{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:33:13Z","timestamp":1791379993455,"version":"4.3.3"},"reference-count":18,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Background\nValproic acid is a mood-stabilizing anticonvulsant. Hepatic injuries are among the occasionally observed adverse effects of this medication.\nCase presentation\nWe present the case of a 47-year-old man who had bipolar disorder for ten years and treated with valproic acid. He demonstrated elevated serum aminotransferases and ultrasonography revealed that hepatomegaly was suggestive of hepatic steatosis.\nConclusion\nThis case report stresses the importance of a complete drug history and the need for clinicians to be aware of the delayed onset of hepatic injuries.<\/jats:p>","DOI":"10.64719\/pb.4348","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"59-62","source":"Crossref","is-referenced-by-count":3,"title":["Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report"],"prefix":"10.64719","volume":"46","author":[{"given":"Leila","family":"Mnif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rim","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev. 2003;9(2):199\u2013216.","DOI":"10.1111\/j.1527-3458.2003.tb00249.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bedry R, Parrot F. Severe valproate poisoning. Re\u00e1nimation. 2004;13:324\u2013333.","DOI":"10.1016\/j.reaurg.2004.03.014"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Zimmerman RI, Ishak KG. Valproate-induced hepatic injury. Analyses of 23 fatal cases. Hepatology. 1982;2:591\u2013597.","DOI":"10.1002\/hep.1840020513"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: A possible association? World J Hepatol. 2015;7(9):1251\u20131257.","DOI":"10.4254\/wjh.v7.i9.1251"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592\u20131609.","DOI":"10.1053\/j.gastro.2012.04.001"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 2003;63(22):2379\u20132394.","DOI":"10.2165\/00003495-200363220-00001"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Powell-Jackson PR, Tredger JM, Williams R. Hepato-toxicity to sodium valproate: a review. Gut. 1984;25(6):673\u2013681.","DOI":"10.1136\/gut.25.6.673"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Scheffner D, Rauterberg-Ruland I, Kochen W, Hofmann WJ. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988;29(5):530\u2013542.","DOI":"10.1111\/j.1528-1157.1988.tb03757.x"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Silva MFB, Aires CCP, Luis PBM et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis. 2008;31:205\u2013216.","DOI":"10.1007\/s10545-008-0841-x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Belcastro V, D\u2019Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Research. 2013;107(1-2):1\u20138.","DOI":"10.1016\/j.eplepsyres.2013.08.016"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Verrotti A, Agostinelli S, Parisi P, Chiarelli F, Coppola G. Nonalcoholic fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 2011;20:382\u2013385.","DOI":"10.1016\/j.yebeh.2010.12.012"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Luef GJ, Waldmann M, Sturm W et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55:729\u2013732.","DOI":"10.1002\/ana.20074"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ortiz-S\u00e1enz de Santa Mar\u00eda R, Santiago-Fern\u00e1ndez C, Cano-Del Pozo M et al. Treatment with valproate and hepatic steatosis. Rev Neurol. 2005;41:766\u2013767.","DOI":"10.33588\/rn.4112.2005135"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56(2):172\u2013177.","DOI":"10.1212\/WNL.56.2.172"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Isoj\u00e4rvi JIT, R\u00e4tty\u00e4 J, Myllyl\u00e4etal VV. Valproate, lamotrigine, and insulin mediated risks in women with epilepsy. Annals of Neurology. 1998;43(4):446\u2013451.","DOI":"10.1002\/ana.410430406"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zhang LF, Liu LS, Chu XM et al. Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats. Acta Pharmacologica Sinica. 2014;35(3):363\u2013372.","DOI":"10.1038\/aps.2013.135"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Silva MF B, Ruiter JPN, Ijlst L et al. Synthesis and intra mitochondrial levels of valproyl-coenzyme A metabolites. Analytical Biochemistry. 2001;290(1):60\u201367.","DOI":"10.1006\/abio.2000.4947"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Aires CC P, Ijlst L, Stet F et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochemical Pharmacology. 2010;79(5):792\u2013799.","DOI":"10.1016\/j.bcp.2009.10.011"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:26:13Z","timestamp":1791314773000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/valproic-acid-and-hepatic-steatosis-a-possible-link-about-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4348","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}